GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Laboratories International Holdings Ltd (FRA:UNJ) » Definitions » Capex-to-Operating-Cash-Flow

United Laboratories International Holdings (FRA:UNJ) Capex-to-Operating-Cash-Flow : 0.80 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is United Laboratories International Holdings Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

United Laboratories International Holdings's Capital Expenditure for the six months ended in Dec. 2023 was €-127.33 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2023 was €159.50 Mil.

Hence, United Laboratories International Holdings's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2023 was 0.80.


United Laboratories International Holdings Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for United Laboratories International Holdings's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Laboratories International Holdings Capex-to-Operating-Cash-Flow Chart

United Laboratories International Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.34 0.32 0.40 0.60

United Laboratories International Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.52 0.35 0.39 0.80

Competitive Comparison of United Laboratories International Holdings's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Laboratories International Holdings's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Laboratories International Holdings's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where United Laboratories International Holdings's Capex-to-Operating-Cash-Flow falls into.



United Laboratories International Holdings Capex-to-Operating-Cash-Flow Calculation

United Laboratories International Holdings's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-187.753) / 313.292
=0.60

United Laboratories International Holdings's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-127.328) / 159.503
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


United Laboratories International Holdings  (FRA:UNJ) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


United Laboratories International Holdings Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of United Laboratories International Holdings's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


United Laboratories International Holdings (FRA:UNJ) Business Description

Traded in Other Exchanges
Address
No. 6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong, HKG
United Laboratories International Holdings Ltd is a major drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Most of the company's sales are generated in China, followed by Europe and India.

United Laboratories International Holdings (FRA:UNJ) Headlines

No Headlines